Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2024-04-10 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references compliance with French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the disclosure of the total number of shares outstanding and voting rights. It provides a table detailing the 'Total number of voting rights' as of March 31, 2024. This type of mandatory, periodic disclosure concerning the capital structure and voting power aligns most closely with regulatory reporting requirements that track ownership thresholds. While it is a specific type of regulatory disclosure, it does not fit perfectly into the defined categories like 10-K, ER, or IR. However, it is a formal regulatory announcement concerning capital structure changes/updates. Since the document explicitly details the total number of voting rights and shares, it is a specific disclosure related to share capital structure. The closest fit among the provided options that deals with share structure updates, although not explicitly a buyback (POS) or new issue (SHA), is the general category for regulatory filings (RNS) or potentially a specific capital update (CAP). Given the focus on the *total number of voting rights* as required by specific French commercial law, this is a mandatory regulatory disclosure. Since there is no specific code for 'Voting Rights Disclosure', RNS (Regulatory Filings) serves as the best general fit for mandatory, non-financial periodic regulatory updates that don't fit elsewhere. It is not a DVA (Declaration of Voting Results) as that refers to the *outcome* of a vote, not the current capital structure count.
2024-04-10 English
Nanobiotix annonce la finalisation de la partie escalade de la Phase 1 et la détermination de la dose recommandée pour la Phase 2 de NBTXR3 dans le traitement du cancer du poumon récurrent, inopérable
Earnings Release Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the finalization of the dose escalation part of a Phase 1 clinical trial (NBTXR3 for recurrent lung cancer) and the determination of the Recommended Phase 2 Dose (RP2D). It details clinical trial progress, safety profiles, and future plans (Phase 2 expansion). This type of announcement, focusing on key clinical trial milestones and results, is characteristic of an Earnings Release (ER) or a general press release related to operational updates. Since it is a press release announcing key operational/clinical results rather than a comprehensive financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these often contain the primary operational highlights that drive investor interest, even if not strictly quarterly financial results. It is not a formal regulatory filing like a 10-K or a specific report like an AR or SR. It is a direct announcement of results, not an announcement *about* a report (RPA). FY 2024
2024-04-02 French
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces the completion of a Phase 1 dose escalation study for a drug candidate (NBTXR3) and the establishment of a recommended Phase 2 dose. This type of announcement, detailing clinical trial progress and key results (safety profile, dose selection), is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing specific clinical milestones rather than a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often contain operational and clinical highlights alongside financial context, or sometimes Regulatory Filing (RNS) if it were a mandatory disclosure. Given the content focuses on clinical trial progress and dose selection, which are key operational updates often bundled with earnings, ER is a strong fit. However, since it is a standalone announcement of clinical progress rather than quarterly financial figures, and it is a formal announcement, it could also be considered a Regulatory Filing (RNS) if it doesn't fit the ER mold perfectly. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical highlight announcement. Since it is a formal press release announcing significant operational/clinical progress, and it is not a specific financial report, it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for important, non-standard announcements, or potentially a Capital/Financing Update (CAP) if the news strongly implies future fundraising, but the primary focus is clinical data. Given the nature of biotech press releases announcing trial milestones, RNS is the safest general classification for non-financial/non-meeting specific announcements.
2024-04-02 English
Nanobiotix to Present at Upcoming Investor Conferences in March
Regulatory Filings Classification · 100% confidence The document is a press release announcing that company management will participate in upcoming investor conferences (fireside chats) in March 2024. It provides dates, times, locations, and presenters for the Leerink Partners Global Biopharma Conference and the Guggenheim Healthy Altitudes Summit. This type of announcement, detailing future investor engagement events rather than releasing financial results, presenting a formal report, or announcing a major corporate action, fits best under the category of Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement related to investor relations activities. Since the document is an announcement *about* future presentations/meetings, and not the presentation material itself, it is not an IP. It is also not a Call Transcript (CT), Earnings Release (ER), or a formal regulatory filing like a 10-K. Given the options, this is a communication aimed at investors regarding future engagement, which often falls under Investor Presentation (IP) if the content is strategic, or RNS if it's a general announcement. However, since the core purpose is to inform investors about management's participation in investor conferences, it is most closely related to investor engagement materials. If the document were announcing the *release* of a presentation, RPA would apply. Since it is announcing *participation* in external events, and it's a short press release, the most fitting category among the specific options that cover investor-facing communications is Investor Presentation (IP), although it is an announcement *of* participation rather than the presentation itself. Given the context of financial reporting databases, announcements about management presenting at major conferences are often grouped with investor presentations or general investor news. Considering the available codes, and that it is not a formal regulatory filing, the closest fit related to investor communication about future events is IP, or RNS as a fallback. Since it is a specific announcement about investor engagement, I will classify it as Investor Presentation (IP) as it pertains to management's forward-looking communication strategy, even though it's just an announcement of attendance. If the document was purely administrative about the release of a report, RPA would be better. Here, it's about management visibility.
2024-03-06 English
Nanobiotix participera à des conférences investisseurs en mars
Report Publication Announcement Classification · 99% confidence The document is a press release titled "NANOBIOTIX PARTICIPERA À DES CONFÉRENCES INVESTISSEURS EN MARS" (NANOBIOTIX WILL PARTICIPATE IN INVESTOR CONFERENCES IN MARCH). It details the dates, times, and participants for the company's presence at the Leerink Partners Global Biopharma Conference and the Guggenheim Healthy Altitudes Summit. This type of announcement, which informs the market about upcoming investor engagement events (like fireside chats or presentations at industry conferences), is best classified as an Investor Presentation (IP) announcement or, more broadly, a communication related to investor relations activities. Since the document itself is an announcement about future participation rather than the presentation material itself, and it is not a standard regulatory filing like 10-K or ER, it fits best under the category related to investor engagement. Given the options, 'Investor Presentation' (IP) is the most relevant category for announcing participation in investor-focused conferences, even if the content is just scheduling details. However, because it is a general announcement about participation rather than the presentation material itself, and it is a press release, it could also be considered a general Regulatory Filing (RNS). Given the specific nature of announcing investor events, IP is a strong candidate, but since it's a press release announcing *participation* rather than the presentation slides or transcript, and it's not a formal earnings release or capital change, I will check the definitions again. The document is a press release announcing executive participation in investor conferences. This is a common activity that precedes or relates to investor presentations. If the document were the actual presentation slides, it would be IP. Since it is an announcement of participation, it is a general corporate communication. Given the options, and recognizing that it is not a formal financial report, the most fitting category for an announcement about investor engagement activities is often grouped with Investor Presentation (IP) or sometimes RNS. Since it is a specific announcement about investor meetings, I will lean towards IP as the intent is investor communication, but I must also consider the 'Menu vs Meal' rule. This is not the 'meal' (the presentation), but an announcement about the 'menu'. Therefore, RPA or RNS might be more accurate if it were just a notice of publication. Since it contains substantive details about *which* conferences and *when*, it is more than just a notice of publication. I will classify it as Investor Presentation (IP) because the core subject matter is investor engagement events.
2024-03-06 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French commercial code (Code de commerce) and AMF regulations (Règlement Général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of January 31, 2024. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific share/capital change notifications. Since it is a monthly update on the total number of shares and voting rights, it is most closely related to changes in the capital structure or major shareholding notifications. However, given the specific nature of reporting total voting rights monthly under AMF rules, it is a specialized regulatory disclosure. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a formal regulatory update concerning the capital structure. Among the options, 'Major Shareholding Notification' (MRQ) deals with ownership thresholds, and 'Share Issue/Capital Change' (SHA) deals with structural changes. Since this is a mandatory monthly disclosure of the *total* count, it fits best as a specific regulatory filing that isn't covered by the more specific financial or corporate action codes. However, in many regulatory contexts, the reporting of total voting rights is often grouped with share capital changes or major holdings. Given the options, and recognizing this is a mandatory disclosure about the composition of capital, it is a specific regulatory filing. If we must choose the closest fit among the provided codes, 'SHA' (Share Issue/Capital Change) is related to the capital base, but 'MRQ' (Major Shareholding Notification) is often used for disclosures related to voting rights thresholds. Since this is a general monthly count, and not a specific threshold breach, it leans towards a general regulatory filing (RNS) or a capital structure update (SHA). Given the explicit focus on 'droits de vote' (voting rights) and 'capital social' (share capital), and the fact that it is a formal, periodic regulatory communication, 'RNS' (Regulatory Filings - fallback) is appropriate, but let's check if it fits 'SHA' better. SHA is for *issues* or *splits*. This is a *report* of the current state. Therefore, 'RNS' is the safest fallback for a specific, non-standard regulatory report. However, in many databases, these specific voting rights reports are sometimes categorized under 'MRQ' or 'SHA'. Since the document explicitly states it will be published again when the numbers change, it is a routine regulatory disclosure. I will classify it as RNS as it is a mandatory regulatory communication that doesn't fit the other specific financial/corporate action codes perfectly, although it touches upon capital structure elements.
2024-02-13 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.